Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mosunetuzumab + iberdomide
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous (mosunetuzumab), Oral (iberdomide)
01
Overview
**Mosunetuzumab + iberdomide** is an investigational combination therapy being studied for **relapsed or refractory B-cell non-Hodgkin lymphoma (NHL)** in adults. Mosunetuzumab is a **bispecific monoclonal antibody**, known as a T-cell engager, that targets both **CD3 on T cells** and **CD20 on B cells**, facilitating T-cell mediated killing of malignant B cells. Iberdomide is a **cereblon E3 ligase modulator (CELMoD)** and immunomodulatory drug (iMiD) that works by blocking the growth of cancer cells and modulating immune cell activity. The combination is intended to leverage complementary mechanisms: enhanced immune modulation (iberdomide) and targeted cytotoxicity (mosunetuzumab). Both agents are being investigated in clinical trials for their efficacy and safety in treating B-cell lymphomas, particularly in patients who have not responded to previous treatments[1][3][4].
- Other names
- mosunetuzumab plus iberdomidemosunetuzumab and iberdomideCC-220 + mosunetuzumab
02
Targets
Beyond the preview
Go deeper on mosunetuzumab + iberdomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mosunetuzumab + iberdomide.